CONCISE REPORT

Serum Interleukin 2 Receptor Levels in Childhood Acute Lymphoblastic Leukemia


The clinical significance of interleukin 2 receptor (IL2R) concentrations in serum was determined for 344 children with newly diagnosed acute lymphoblastic leukemia (ALL). Serum levels of IL2R in patients (267 to 80,000 U/mL, median 2,007 U/mL) were significantly higher than normal control values (170 to 738 U/mL, median 347 U/mL) (P < .0001). Measurements in cases of T cell ALL were lower than in the non-T, non-B cases (P = .02). Among the 264 patients with non-T, non-B ALL, but not in those with T cell disease, higher serum IL2R levels (>2,000 U/mL) were associated with a poorer treatment outcome (P = .04). In a multivariate analysis, serum IL2R level contributed independent prognostic information beyond that conveyed by leukocyte count, race, and age (P = .04). One explanation for these results is that soluble IL2R competes with normal lymphocyte-integrated IL2R for the ligand and thus could suppress host antitumor immunity.

© 1988 by Grune & Stratton, Inc.

From the Departments of Hematology-Oncology, Pathology and Laboratory Medicine, and Biostatistics and Information Systems, St Jude Children’s Research Hospital; and the Division of Hematology-Oncology, Department of Pediatrics, The University of Tennessee, College of Medicine, Memphis; and T Cell Sciences Inc, Cambridge, MA.


Supported by grants No. CA-20180 and CA-21765 from the National Cancer Institute and by the American Lebanese Syrian Associated Charities (ALSAC).

Address reprint requests to Dr Ching-Hon Pui, St Jude Children’s Research Hospital, PO Box 318, Memphis, TN 38101.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. §1734 solely to indicate this fact.

© 1988 by Grune & Stratton, Inc.

0006-4971/88/7104-0057$3.00/0


From www.bloodjournal.org by guest on November 15, 2017. For personal use only.
leukemia, for instance, serum levels of the receptor were correlated with disease-free remissions after therapy with recombinant α-interferon.13 In Hodgkin’s disease, high serum IL2R levels were associated with the presence of constitutional symptoms.14 In B-cell chronic lymphocytic leukemia, lower levels of serum IL2R were found in patients with less invasive disease, and cases with the lowest levels had T cells showing the best mitogenic response and helper capacity.17 We and other researchers8,10 have demonstrated independent prognostic significance for serum IL2R in patients with non-Hodgkin’s lymphoma; that is, higher levels were associated with more advanced disease, greater tumor burden, and a poorer outcome.

Because soluble IL2R is capable of binding IL2,4 it might downregulate the host immune response by competing with normal lymphocyte cellular IL2R for the ligand. In this regard, increased serum levels of IL2R have been suggested to enhance neoplastic growth by suppressing host antitumor immunity in patients with lymphoid malignancies.8,9,10

The lack of prognostic value of serum IL2R levels in our patients with T-cell ALL could be related to the small number of cases that were studied. Alternatively, the use of effective intensive chemotherapy could have abolished any prognostic influence exerted by IL2R concentrations.18 Such loss has been observed repeatedly for other factors in treatment programs featuring intensified chemotherapy.14

HTLV-positive T cell lines constitutively express cell surface IL2R and release large amounts of IL2R into supernatant.6 In patients with lymphoma, the demonstration of IL2R on tumor cells19-21 and in high levels in the malignant serous effusions19 suggest that the serum IL2R in them was derived from tumor cells. The source of high serum IL2R in our patients is unclear. In one study of 38 cases of ALL, only two CD19+ (B4+) cases had a low percentage of blasts expressing cell surface IL2R.19 Using flow cytometry, we studied 74 consecutive cases of childhood ALL and found that only one of 11 T cell cases and one of 63 non-T, non-B cases expressed cellular IL2R detectable by binding to a CD25 monoclonal antibody (F.G. Behm, unpublished observations, 1987). Several studies, however, have shown that blast cells with a common ALL, pre-B or T-cell phenotype can be induced to express IL2R after in vitro activation.22-24

Leukemic cells outside the circulation may be more likely to express and release IL2R, especially in cases with a poor prognosis. On the other hand, IL2R-bearing lymphocytes were found in patients with a variety of benign reactive lymphoid processes20 and increased serum IL2R levels have been found in some benign clinical conditions.25 Thus, further studies are needed to define the source, the structure, and the immunoregulatory role of soluble IL2R in patients with ALL; such information would aid in understanding the lower serum IL2R levels we observed in patients with T-cell ALL. Finally, the value of sequential measurements of soluble IL2R in identifying cases in which relapse is apt to occur should be tested in a prospective manner.

NOTE ADDED IN PROOF

We recently learned that normal children less than 6 years of age have significantly higher serum IL2R levels than do adults.26,27 Even so, the vast majority (95%) of children in those studies had receptor
concentrations <2,000 U/mL, the dividing point used in our analysis.

ACKNOWLEDGMENT

We thank J. Gilbert for editorial review and P. Vandiveer for typing the manuscript.

REFERENCES

Serum interleukin 2 receptor levels in childhood acute lymphoblastic leukemia

CH Pui, SH Ip, S Iflah, FG Behm, BH Grose, RK Dodge, WM Crist, WL Furman, SB Murphy and GK Rivera

Updated information and services can be found at:
http://www.bloodjournal.org/content/71/4/1135.full.html

Articles on similar topics can be found in the following Blood collections

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml